Shanghai Bioling Biotechnology

Shanghai Bioling Biotechnology is the primary innovative biologics research and development subsidiary of Huadong Medicine, located in Shanghai's Zhangjiang Hi-Tech Park. The company serves as a central innovation hub, focusing on the discovery and clinical development of advanced therapies including monoclonal antibodies, antibody-drug conjugates (ADCs), and metabolic regulators. Its robust pipeline is headlined by Mirvetuximab soravtansine, a first-in-class ADC targeting folate receptor alpha for ovarian cancer, and several next-generation GLP-1 receptor agonists for diabetes and obesity. Shanghai Bioling plays a pivotal role in Huadong Medicine's strategic transition toward high-value innovative medicines, leveraging a global network of partnerships with companies like ImmunoGen and Heidelberg Pharma. The company integrates state-of-the-art technology platforms to address significant unmet needs in oncology, endocrinology, and autoimmune disorders.